Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a clinical study titled Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI. The study aims to evaluate the adverse events and changes in disease activity associated with the investigational drug telisotuzumab adizutecan, compared to the standard of care in treating non-small cell lung cancer (NSCLC).
The study tests telisotuzumab adizutecan, an investigational intravenous drug, intended to treat NSCLC. It is administered in two phases: Phase 2 involves two different doses, while Phase 3 uses the recommended dose from Phase 2 or the standard of care.
This interventional study is randomized with a sequential intervention model and no masking, focusing on treatment. Approximately 430 participants will be enrolled globally over 69 months.
The study is set to begin on August 28, 2025, with primary completion and estimated completion dates not yet specified. The last update was also on August 28, 2025, indicating the study is not yet recruiting.
For investors, this study could influence AbbVie’s stock performance, as successful results may enhance the company’s competitive position in the NSCLC treatment market. The pharmaceutical industry closely watches such developments, given the potential impact on market dynamics and investor sentiment.
The study is ongoing, with further details available on the ClinicalTrials portal.